G 001
Alternative Names: G-001; G001 - BUZZZ PharmaceuticalsLatest Information Update: 25 Apr 2023
At a glance
- Originator BUZZZ Pharmaceuticals
- Class Antirheumatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 10 Jan 2023 BUZZZ Pharmaceuticals and Veristat complete a phase II trial in Osteoarthritis (Treatment-experienced, In adult, In the elderly) in Canada (Topical) (NCT05007808)